| Revenue growth | 12% QoQ growth to ₹342cr; base business at multi-quarter highs. |
|---|---|
| Margins | Consolidated EBITDA 16%; base business at 26%, Ibuprofen remains negative. |
| Order book | Healthy order book driven by base business and customer wallet share. |
| Demand visibility | Strong order book in base business; focus on new geographies. |
| Management confidence | Balanced; optimistic on base business but cautious on Ibuprofen legacy issues. |
Growth
12% QoQ revenue growth; base business margins at 26% EBITDA. Growth is structurally driven by customer base expansion.
Outlook
Targeting debt reduction to sub-₹503cr by end-May 2026; filing 4-5 new DMFs annually starting FY26.
Risks
Persistent Ibuprofen headwinds causing negative EBITDA; strategic review of Ibuprofen/Vizag assets creates medium-term uncertainty.
Earnings Call filed with NSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹739.15
- Market cap
- ₹3,552 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2192.7×Sector 50.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara achieved record EBITDA/PAT despite significant geopolitical headwinds in West Asia impacting raw material costs.
- Call
- Guides 10% growth
Solara Active Pharma Sciences Q1 FY27 Results: Net Profit ₹16.3 Cr, Up 55.2% YoY
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹381.6 Cr (+19.6% YoY) and net profit of ₹16.3 Cr (+55.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹16.3 Cr · +55.2% YoY
Solara Active Pharma Sciences Earnings Call: Key Takeaways
Solara delivered its highest Q4 revenue in 8 quarters at INR 392cr, driven by a strong base business with 54% gross margins, despite persistent headwinds and negative EBITDA in the Ibuprofen segment.
Solara Active Pharma Sciences Q4 FY26 Results: Turns Profitable, Net Profit ₹9.6 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹387.3 Cr (+41.9% YoY) and net profit of ₹9.6 Cr for Q4 FY26.
- Key figure
- Net profit ₹9.6 Cr